| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/14/2010 | CA2730408A1 Influenza hemagglutinin and neuraminidase variants |
| 01/14/2010 | CA2730391A1 Delivery of dry formulations of octreotide |
| 01/14/2010 | CA2730325A1 Composition |
| 01/14/2010 | CA2730316A1 Peptide inhibitors of cd40l signaling and uses therefor |
| 01/14/2010 | CA2730290A1 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes |
| 01/14/2010 | CA2730273A1 Nanotube-reinforced balloons for delivering therapeutic agents within or beyond the wall of blood vessels, and methods of making and using same |
| 01/14/2010 | CA2730203A1 Complement antagonists and uses thereof |
| 01/14/2010 | CA2730201A1 Pharmaceutical composition for treatment and prevention of cancer |
| 01/14/2010 | CA2730108A1 Cyclosporin derivatives for treating ocular and dermal diseases and conditions |
| 01/14/2010 | CA2730088A1 Immunity-inducing agent and method for detection of cancer |
| 01/14/2010 | CA2729605A1 Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa |
| 01/14/2010 | CA2729351A1 Fn14/trail fusion proteins |
| 01/14/2010 | CA2728351A1 Peptidylarginine deiminase (pad) inhibitors |
| 01/14/2010 | CA2728213A1 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| 01/14/2010 | CA2727574A1 Multi-leu peptides and analogues thereof as selective pace4 inhibitors and effective antiproliferative agents |
| 01/14/2010 | CA2727388A1 Anti-tumor immunotherapy |
| 01/14/2010 | CA2726945A1 Polypeptides involved in the neuroregeneration-promoting properties of olfactory ensheathing glia |
| 01/14/2010 | CA2670964A1 Use of composition for manufacture of medicant and method for inhibiting formation of body fat |
| 01/13/2010 | EP2143794A1 Viral vector for gene therapy |
| 01/13/2010 | EP2143790A1 A purified recombinant batroxobin with high specific activity |
| 01/13/2010 | EP2143736A1 Hydroxyalkyl starch derivatives |
| 01/13/2010 | EP2143733A1 ANTI-IL-20 antibodies and binding partners and methods of using in inflammation |
| 01/13/2010 | EP2143731A1 Compounds for immunotherapy of prostate cancer and methods for their use |
| 01/13/2010 | EP2143730A2 Modified peptides and their use for the treatment of autoimmune diseases |
| 01/13/2010 | EP2143442A1 Treatment of solid tumors with tissue inhibitors of metalloproteinases(TIMPs) |
| 01/13/2010 | EP2143439A1 Protective agent for transplanted organ |
| 01/13/2010 | EP2143438A1 Compositions and methods for the diagnosis and treatment of tumor |
| 01/13/2010 | EP2143437A1 Compositions and methods for the diagnosis and treatment of tumor |
| 01/13/2010 | EP2143436A1 Protein product for treatment of infectious diseases and related inflammatory processes |
| 01/13/2010 | EP2142669A2 Sirtuin based methods and compositions for treating b- catenin-related conditions |
| 01/13/2010 | EP2142660A2 Methods and systems for o-glycosylating proteins |
| 01/13/2010 | EP2142572A1 Tgfp-cap peptide and its uses |
| 01/13/2010 | EP2142566A1 Methods and compositions for the treatment of proliferative diseases |
| 01/13/2010 | EP2142563A1 Bis-met histones |
| 01/13/2010 | EP2142256A1 Treatment of obesity |
| 01/13/2010 | EP2142222A2 Fibrin gel for controlled release of tgf-beta and uses thereof |
| 01/13/2010 | EP2142207A1 Pharmaceutical formulations of ghrh molecules |
| 01/13/2010 | EP2142206A1 Method of treating ischemic disorders |
| 01/13/2010 | EP2142205A1 Compositions and methods for increasing vascularization |
| 01/13/2010 | EP2142174A1 Stable aqueous g-csf formulations |
| 01/13/2010 | EP1755642B1 Annexin v for preventing plaque rupture |
| 01/13/2010 | EP1701737B1 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| 01/13/2010 | EP1660095B1 Tricyclic parp inhibitors |
| 01/13/2010 | EP1628677B1 Protein stabilization in solution |
| 01/13/2010 | EP1558749B1 Atypical protein kinase c isoforms in disorders of the nervous system and cancer |
| 01/13/2010 | EP1499886B1 Methods and compositions for inducing an immune response |
| 01/13/2010 | EP1360500B1 Methods for selective targeting |
| 01/13/2010 | EP1341550B1 Leptin for treating respiratory distress syndrome and impaired lung surfactant production |
| 01/13/2010 | EP1339744B1 Production of recombinant bmp-2 |
| 01/13/2010 | EP1323415B1 Method of coating fine particle with lipid film |
| 01/13/2010 | EP1305322B1 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 01/13/2010 | EP1144388B1 Acyl derivatives which treat vla-4 related disorders |
| 01/13/2010 | CN101626780A HAT acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| 01/13/2010 | CN101626779A Oral disinfectant, food additive comprising the disinfectant |
| 01/13/2010 | CN101626778A Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies |
| 01/13/2010 | CN101626777A Immunophilin ligands and methods for modulating immunophilin and calcium channel activity |
| 01/13/2010 | CN100580087C Conjugation of peptides |
| 01/13/2010 | CN100580085C Adenovirus/alpha virus hybrid vector for the effective administration and expression of therapeutic genes in tumour cells |
| 01/13/2010 | CN100580082C Lyophylization preparation of recombinant staphylokinase, its preparing method and application |
| 01/13/2010 | CN100580080C Corona-virus-like particles comprising functionally deleted genomes |
| 01/13/2010 | CN100579989C Interfusion protein between diphtheria toxin and GM-CSF mutant, coded gene and application |
| 01/13/2010 | CN100579988C Interfusion protein between diphtheria toxin and GM-CSF mutant, coded gene and application |
| 01/13/2010 | CN100579987C Liver target fusion protein with siRNA guiding effect |
| 01/13/2010 | CN100579984C Orally administered peptides to ameliorate atherosclerosis |
| 01/13/2010 | CN100579582C Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the preparation of medicament for treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of aller |
| 01/13/2010 | CN100579577C Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| 01/13/2010 | CN100579576C Entoptic embedding material for preventing aggravation of nearsightedness |
| 01/13/2010 | CN100579575C Polypeptide protein class-medicament under-tongue instant nanometer emulsion and 3D printing preparing method thereof |
| 01/13/2010 | CN100579574C Brain protein hydrolyte freeze-drying preparation for injection and its making method |
| 01/12/2010 | US7645861 Modified Fc molecules |
| 01/12/2010 | US7645860 Proteinaceous construct comprising a Factor VIII molecule conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII; for prolonging in vivo-half-life of FVIII in the blood of a mammal having a bleeding disorder associated with functional defects or deficiencies of FVIII |
| 01/12/2010 | US7645797 Gamma aminobutyric acid antagonist such as naphthylalanine; antiepileptic agents; antidepressants; anxiolytic agents; psychological disorders; neurodegenerative diseases; analgesics; drug withdrawal |
| 01/12/2010 | US7645795 Administering a nutritional supplement phosphatidylcholine, linoleic acid and alpha linoleic acid in combination with mineral; inhibit the disease progression or delay the symptoms; using nutraceuticals to treat neurodegenerative diseases |
| 01/12/2010 | US7645744 Compositions and methods for siRNA inhibition of HIF-1 alpha |
| 01/12/2010 | US7645742 administering a formulation containing creatine, L-arginine- alpha -ketoglutarate, D-ribose, L-carnitine, L-citrulline, and pyruvate to a mammal performing a physical activity 15-30 minutes before initiation of the physical activity; increases endurance and muscle mass of the person |
| 01/12/2010 | US7645741 IAP BIR domain binding compounds |
| 01/12/2010 | US7645740 Peptide sequence found in Laminin 5 for treating skin impairments |
| 01/12/2010 | US7645739 Modified annexin compositions and methods of using same |
| 01/12/2010 | US7645738 18-membered nitrobenzyl- and aminobenzyl-substituted cyclohexadepsipeptides for controlling endoparasites and a process for their preparation |
| 01/12/2010 | US7645736 injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid |
| 01/12/2010 | US7645735 administering to a patient in need of prevention of endometrosis, a therapeutically effective amount of a peptide, consisting of 10 to 35 amino acids of the N-terminal region of a human endostatin protein including the first histidine of the endostatin protein or variant |
| 01/12/2010 | US7645734 Compositions and methods for treating and preventing heart tissue degeneration and uses thereof |
| 01/12/2010 | US7645733 Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| 01/12/2010 | US7645595 Culturing epidermal keratinocytes on collagen gel layer containing human fibroblasts, exposing to air, and culture contains matrix metalloproteinase inhibitor such as N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride |
| 01/12/2010 | US7645454 Prostate specific antigens and uses thereof |
| 01/12/2010 | US7645452 RTVP based compositions and methods for the treatment of prostate cancer |
| 01/12/2010 | US7645451 Treating a subject at risk of a tumor characterized by aberrant Dkk-1 expression using e.g. antibody, antisense agent |
| 01/12/2010 | US7645449 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 01/12/2010 | US7645448 Prevention, therapy of pathogen infections; anchoring on surface of target cells; viricides; gene therapy; neuraminidase activity; antiallergens; antiinflammatory agents |
| 01/12/2010 | US7645447 Treating retinal degeneration caused by retinal vein occlusion or retinal ischemia |
| 01/12/2010 | US7645446 Glutamic acid decarboxylase (GAD) based delivery system |
| 01/12/2010 | US7645445 Purified mammalian cytokine IL-174 polypeptides |
| 01/12/2010 | US7645441 Compositions and methods in cancer associated with altered expression of PRLR |
| 01/12/2010 | CA2443365C Methods for the recombinant production of antifusogenic peptides |
| 01/12/2010 | CA2438143C Modified proteins, designer toxins, and methods of making thereof |
| 01/12/2010 | CA2407298C Mixtures of triblock polyesterpolyethylene glycol copolymers |
| 01/12/2010 | CA2402339C Viral antigen and vaccine against isav (infectious salmon anaemia virus) |
| 01/12/2010 | CA2373281C Methods of treating diabetes using a complex of igf-1 and igfbp-3 |
| 01/12/2010 | CA2351558C Peptide fragments having cell death inhibitory activity |
| 01/12/2010 | CA2331846C Expression vectors for stimulating an immune response and methods of using the same |